Steve Silvestro: Yes, I mean we’re not going to give sort of guidance on the quarter outside of what we’ve already done, Eric. But I think we can say we’ve got two components that we’re looking at, right, recognized revenue as a form of what we report and the backlog in terms of forward-looking success. And so I think what we can say we said on that, Will, I don’t know if you want to add anything else?
Will Febbo: Yes. No, that’s right. And I think it doesn’t surprise me that pharma is not rushing the year just given everything going on. But I will say that the lean — we’re seeing, we’re seeing it through RPs, we’re seeing it through what we have in backlog, we’re seeing it through conversations, and seriousness of some of our partners at the agency level looking at much bigger engagement. So, yes, the telltales are there for a good year. Again, just trying to really be conservative on this one, Eric.
Eric Martinuzzi: Okay. And then, Ed, you talked about — I think the Q4 GAAP operating expense was $13.3 million, what should we think about for operating expense for Q1?
Ed Stelmakh: Yes. So, — Yes. I got it. Thanks Eric. So, obviously, we don’t guide on our operating expenses. But what I can tell you is there will be probably an uptake, just given the fact that we are setting bonuses for the year. There will be a full year impact of a few FTEs that we hired in 2022. And I think those two factors probably will give us a bit of an uptick. But generally speaking, the run rate to be pretty contained. We’re not expecting any major investments certainly in the earlier part of the year.
Eric Martinuzzi: Got it. Thanks for taking my questions.
Will Febbo: Thanks Eric.
Operator: There are no further questions at this time. Please proceed.
Will Febbo: Thank you, operator. So, we’re in an industry that is truly entering a generational paradigm shift in the way technology enables and drives better patient care and outcomes. I say this as a backdrop, given the importance of our businesses move from tactical to strategic deals, which are growing increasingly larger in value. In line with this industry change, the run rate for closing deals are no longer and require additional buy-in from our stakeholders. That said, we truly believe that we have the right platform in place to deliver on the promise of improved outcomes, utilizing our solutions, in particular, RWD-AI. Moreover, our robust portfolio of omnichannel services are expanding outside of the EHR, and we continue to improve patient outcomes while driving our strong ROIs for our customers.
We’ve also built the team and a culture as a company, which gives us a distinct competitive advantage as we focus on our clients, partners, and investors. In 2023, we have our financial and operational goals firmly underpinned by our best-in-class platform and the ability to access distribute and use the next generation of real-world data-enabled insights across the largest in workflow point-of-care network in the US. As such, we look forward to making a positive impact across our pharma prescriber and patient stakeholder base for the years to come. We want to thank everyone, employees, shareholders, customers, and partners alike as we continue to build out our solutions on a one unified omnichannel platform and look forward to reporting on our progress on our next earnings call and several investor conferences.
Thank you. Operator?
Operator: Thank you, sir. Before we conclude today’s call, I would like to provide the company’s safe harbor statement that includes important cautions regarding forward-looking statements made during today’s call. Statements made by management during today’s call may contain forward-looking statements within the definition of Section 27A and the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934 as amended. These forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible and seeking and similar expressions identify forward-looking statements. They may speak only to the date that such statements are made. Such forward-looking statements in this call include statements regarding estimation of total addressable market size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments, growth opportunities, acquisitions and upcoming announcements.
They also include the management’s expectations for the rest of the year. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth and contemplated by or underlying these forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition, and other material risks. Risks and uncertainties to which forward-looking statements are subject to could affect business and financial results are included in the company’s annual report on Form 10-K for the quarter ended December 31st, 2022.
This Form is available on the company’s website and on the SEC website at sec.gov. Before we end today’s conference, I would like to remind everyone that this call will be available for replay via webcast only starting later this evening, running through for a year. Please refer to today’s press release for replay instructions available via the company’s website at www.optimizerx.com. Thank you for joining us today. This concludes today’s conference call. You may now disconnect your lines.
